Summary
This is a Phase 1/2, open-label, non-randomized, 4-part Phase 1 trial to determine the
safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2
dose (RP2D) of INBRX 106 administered as a single agent or in combination with the
anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda).